Loss of LATS1/2 or other Hippo pathway alterations could confer resistance to erlotinib in HNSCC cells with EGFR overexpression or lung adenocarcinoma cells harboring EGFR mutations. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.